In: Nursing
Antonia Lopez is a 43-year-old Hispanic woman. Mrs. Lopez was recently diagnosed with carcinoma of the breast. She is receiving chemotherapy with vincristine (Oncovin). She is also receiving filgrastim (Neupogen) to treat neutropenia during chemotherapy.
What are the common adverse reactions seen with the use of filgrastim (Neupogen)?
Filgrastim (Neupogen) is what type of immunostimulant drug, and what is its mechanism of action?
Filgrastim is used to treat neutropenia, an order in which the body creates too a small number of neutrophils. Neutropenia may be a very old situation in which the body does not make sufficient neutrophils or it may be reason by drugs used to care for cancer. In some cases, the body may create sufficient neutrophils but, as part of cancer behavior, the doctor may want to raise the number of sure blood cells (CD34 cells) and bring together them. The cells are calmed using a method called aphaeresis. These composed cells are given back to the patient behind receiving very high doses of treatment for cancer to assist the blood counts to get back to normal more rapidly.
Filgrastim is a logically happening cytokine glycoprotein that motivates propagation, separation, and functional movement of neutrophils, causing a rapid increase in WBC counts within 2 to 3 days in patients with normal bone core function or 7 to 14 days in patients with bone core repression. Blood counts return to pretreatment levels, typically within 1 week after therapy ends.
Filgrastim is a human granulocyte colony exciting factor (G-CSF) formed by recombinant DNA technology. G-CSF controls the manufacture of neutrophils within the bone marrow; endogenous G-CSF is a glycoprotein formed by monocytes, fibroblasts, and endothelial cells.
G-CSF is a colony inspiring issue which has been exposed to have negligible direct in vivo or in vitro effects on the making of other hematopoietic cell types. filgrastim(Neupogen) is the name for recombinant methionyl person granulocyte-colony motivating issue